About this document

Camrelizumab and Apatinib in Cancer Treatment by florentinagbrl8 is a document available to read on EtoBox.

This systematic review evaluates the safety and efficacy of camrelizumab, a PD-1 monoclonal antibody, and its combination with apatinib in treating various solid cancers. The review found that camrelizumab alone has an overall response rate (ORR) of 20.2% and a disease control rate (DCR) of 45.8%, while the combination therapy shows improved efficacy with an ORR of 41.8% and a DCR of 82.4%. Adverse events were noted, with common ones including fatigue and liver enzyme increases, indicating that while the tr

Author

florentinagbrl8

Language

EN